HLUNA (HLUNA) News
Follow HLUNA (HLUNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Xeris Biopharma NASDAQ:XERS, Bloomberg News reported on Tuesday, citing people familiar with the matter.
NEWS | Sep 29, 2026, 05:02 PM UTC
L
Lundbeck Is Said To Express Interest In Buying Xeris Biopharma - Bloomberg News
H Lundbeck A/S OMXCOP:HLUN_A
NEWS | Sep 29, 2026, 04:47 PM UTC
L
H. Lundbeck A/S (HLUN_A) To Relocate US HQ To Greater Boston, Create Global Innovation Hub
H. Lundbeck A/S will relocate its US headquarters from Deerfield, IL, to Greater Boston and establish a global innovation hub to scale its neuroscience portfolio, expand innovation opportunities, and build digital/AI cap
NEWS | Sep 25, 2026, 07:08 AM UTC
L
Lundbeck to establish global innovation hub in Greater Boston and relocate US headquarters
COPENHAGEN, Denmark and CHICAGO, 25 September 2026 // -- H. Lundbeck A/S (Lundbeck) today announced that it will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, where the company
NEWS | Sep 25, 2026, 07:08 AM UTC
L
Lundbeck To Establish Global Innovation Hub In Boston
H Lundbeck A/S OMXCOP:HLUN_A
NEWS | Sep 25, 2026, 06:04 AM UTC
M
Lundbeck’s Vyepti gets Japan marketing authorization
Japan’s MHLW granted marketing authorization for Lundbeck’s Vyepti (eptinezumab) to help prevent migraine attacks in adults, citing global Phase III and Japan-specific studies.
REGULATION | Sep 16, 2026, 06:24 AM UTC
M
Lundbeck gets Japan marketing authorization for Vyepti to prevent migraines
Lundbeck said Japan’s MHLW granted marketing authorization for eptinezumab (Vyepti) for preventing migraine attacks in adults.
REGULATION | Sep 16, 2026, 06:23 AM UTC
M
Lundbeck receives marketing authorization for Vyepti in Japan
H Lundbeck said it has received marketing authorization for Vyepti in Japan.
REGULATION | Sep 16, 2026, 06:09 AM UTC
L
H. Lundbeck A/S (OMXCOP:HLUN_A) Completes Randomization in Phase III Dravet Trial
H. Lundbeck A/S said the last patient has been randomized in DEEp SEA, a global Phase III trial of bexicaserin for seizures in Dravet syndrome; over 100 participants enrolled, with an option to enter a 52-week open-label
NEWS | Sep 15, 2026, 07:34 AM UTC
L
Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome
VALBY, Denmark, 15 September, 2026 // -- H. Lundbeck A/S (Lundbeck) today announced that the last patient has been randomized in DEEp SEA (NCT06660394), a global Phase III clinical trial evaluating the efficacy, safety a
NEWS | Sep 15, 2026, 07:33 AM UTC
L
Lundbeck Target Cut to DKK36.00 From DKK40.00 by Deutsche Bank
Lundbeck Target Cut to DKK36.00 From DKK40.00 by Deutsche Bank
NEWS | Sep 15, 2026, 06:32 AM UTC
L
Lundbeck Cut to Sell From Hold by Deutsche Bank
Lundbeck Cut to Sell From Hold by Deutsche Bank
NEWS | Sep 15, 2026, 06:32 AM UTC
L
Lundbeck to present preclinical bexicaserin dual-mode data at European Epilepsy Congress
Lundbeck said preclinical data on bexicaserin’s dual mode of action will be featured in an oral presentation at the European Epilepsy Congress in Athens, Greece, 5–9 September.
GEOPOLITICS | Sep 03, 2026, 07:39 AM UTC